Israël - hébreu - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 10000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israël - hébreu - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israël - hébreu - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israël - hébreu - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israël - hébreu - Ministry of Health

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 50 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

Israël - hébreu - Ministry of Health

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 100 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

Israël - hébreu - Ministry of Health

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 150 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

Israël - hébreu - Ministry of Health

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 200 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

Israël - hébreu - Ministry of Health

tzamal bio-pharma ltd - quetiapine as fumarate - טבליות בשחרור ממושך - quetiapine as fumarate 50 mg - quetiapine - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should

Israël - hébreu - Ministry of Health

tzamal bio-pharma ltd - quetiapine as fumarate - טבליות בשחרור ממושך - quetiapine as fumarate 200 mg - quetiapine - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should